ArticleFrontiers in immunology2026
Transcriptomic profiling of autoimmune hepatitis identifies TRAT1 as an
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EprX associates with concurrent shifts in antimicrobial resistance and virulence in clinical bloodstreamFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T cell receptor-associated transmembrane adaptor 1 (TRAT1) is a well-characterized regulator of T-cell signaling, yet its functional roles in innate lymphocytes remain largely undefined. This study aimed to identify autoimmune hepatitis (AIH)-associated immune targets and perform an exploratory functional characterization of TRAT1 in NK-cell models. Methods: We performed transcriptomic analysis on liver tissues from AIH patients and disease controls to prioritize candidate genes. Public datasets and a Concanavalin A (ConA)-induced acute immune-mediated hepatitis murine model were used for contextualization and experimental support for Trat1 expression and immune cell dynamics. The functional role of TRAT1 in NK cells was assessed using NK92-MI cells and primary human NK cells with siRNA-mediated TRAT1 knockdown (KD). TRAT1 expression kinetics and cytotoxicity were examined in both systems, whereas proliferation, effector molecule production, surface receptor expression, calcium flux, and mitogen-activated protein kinase (MAPK) signaling were further analyzed in NK92-MI cells. Results: TRAT1 was prioritized as an AIH-enriched immune-related candidate gene in this discovery cohort. In the ConA-induced acute immune-mediated hepatitis model, Conclusion: Through an exploratory transcriptomic discovery approach, this study suggests that TRAT1 acts as an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.